drugset / Trial / NCT00655369
A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In a Phase II trial in subjects with nonrestorative sleep, PD 0200390 demonstrated a positive treatment effect relative to placebo on the primary endpoint, the weekly version of the Restorative Sleep Questionnaire (RSQ-W). In this study, the dose-response relationship of varying doses of PD 0200390 using the Restorative Sleep Questionnaire (RSQ-W), will be explored in Nonrestorative Sleep subjects.
Timeline
- Start
- 2008-04
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATAGABALIN | Small molecule | 5 mg | Oral |
| Subject | ATAGABALIN | Small molecule | 15 mg | Oral |
| Subject | ATAGABALIN | Small molecule | 25 mg | Oral |
| Subject | ATAGABALIN | Small molecule | 35 mg | Oral |
| Subject | ATAGABALIN | Small molecule | 50 mg | Oral |